BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 8.11 -0.04 (-0.49%) Market Cap: 1.68 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Q3 2019 BioCryst Pharmaceuticals Inc Earnings Call and Update on the Commercial Opportunity Transcript

Nov 06, 2019 / 01:00PM GMT
Release Date Price: $2.01 (-0.99%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the BioCryst third quarter corporate update. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Mr. John Bluth at BioCryst. Please go ahead, sir.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Thanks very much, Skyler. Good morning, and welcome to our call. Today's press releases and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; Chief Medical Officer, Dr. Bill Sheridan; CFO, Tom Staab; Chief Business Officer, Megan Sniecinski; and Charlie Gayer and Jinky Rosselli from our commercial leadership team. Following our remarks, we'll answer your questions.

Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an investment in BioCryst. As detailed on the slide, today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot